SCHEMBL6773808

SCHEMBL6773808

O=C1N=NC(=O)c2cc(Br)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.56
PTPRC P08575 1/20 0.48
BCL2 P10415 2/20 0.47
MCL1 Q07820 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
TGM2 P21980 1/20 0.41
CES1 P23141 1/20 0.41
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
HSP90AA1 P07900 1/20 0.39
TLR9 Q9NR96 1/20 0.39
METAP1 P53582 1/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.38
PARP10 Q53GL7 2/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4141951 0.86 S100A4 (0.56) S100A4PTPRCBCL2MCL1CA1
SCHEMBL28901830 0.82 S100A4 (0.46) S100A4PTPRCBCL2MCL1CA1
SCHEMBL5188643 0.76 ESR1 (0.56) PTPRCCA1CA2CA7CA9
SCHEMBL29775081 0.74 S100A4 (0.48) S100A4PTPRCBCL2MCL1CA1
SCHEMBL20529361 0.74 S100A4 (0.48) S100A4PTPRCBCL2MCL1CA1
SCHEMBL3485419 0.74 S100A4 (0.48) S100A4PTPRCBCL2MCL1CA1
SCHEMBL393320 0.74 BCL2 (0.50) S100A4PTPRCBCL2MCL1CA1
SCHEMBL17141524 0.74 S100A4 (0.48) S100A4PTPRCBCL2MCL1CA1
Hydrochloric Acid SCHEMBL2099531 0.73 S100A4 (0.47) S100A4PTPRCBCL2MCL1CA1
Hydrochloric Acid SCHEMBL2097036 0.73 S100A4 (0.47) S100A4PTPRCBCL2MCL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699870-B2 Phthalazine compounds and therapeutic agents for erectile dysfunction EISAI CO., LTD. (JP) 2004-03-02 US disclosed
US-20030105074-A1 Phthalazine compounds and therapeutic agents for erectile dysfunction EISAI CO., LTD. 2003-06-05 US disclosed
US-6498159-B1 SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE EISAI CO., LTD. (JP) 2002-12-24 US disclosed
EP-1057819-A1 PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION Eisai Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105074-A1 Phthalazine compounds and therapeutic agents for erectile dysfunction CLIC1, CBR1, CBR3 S100A4 4773/4885PTPRC 3625/4885BCL2 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.